Literature DB >> 2522027

Correlation between heart disorders and concentrations of directly measured atrial natriuretic peptide in plasma.

L Fridrich1, T Szekeres, E Hartter, F Schweighofer, A Gassner, A Laczkovic.   

Abstract

We used new commercially available direct radioimmunoassay to measure human atrial natriuretic peptide (h-ANP) in plasma from 48 individuals who were being evaluated for left and right ventricular function. For 13 healthy individuals with normal ventricular function these concentrations ranged up to 54 ng/L. Measurements of h-ANP clearly differentiated between normal subjects, patients with coronary artery disease, and patients who had undergone orthotopic heart transplantation (ANOVA P less than 0.0001, significant differences between all groups)--all showing normal ventricular function at rest. There was a strong negative correlation (r = -0.64, P less than 0.001) between left ventricular ejection fraction and h-ANP concentrations in plasma of patients with proven coronary artery disease, patients with cardiomyopathy, and healthy individuals. Results by the present method and methods involving extraction of the sample correlated well. Evidently the direct assay of h-ANP in plasma yields information that could be used to help evaluate heart disorders and other pathophysiological conditions causing increased h-ANP concentrations in plasma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522027

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Uncoupling of atrial natriuretic peptide and cyclic guanosine 3',5'-monophosphate production in patients with liver cirrhosis.

Authors:  K P Vorderwinkler; G Jakob; J Mair; G Judmaier; B Puschendorf
Journal:  Clin Investig       Date:  1994-01

2.  Atrial natriuretic factor responses to submaximal and maximal exercise.

Authors:  K Mandroukas; A Zakas; N Aggelopoulou; K Christoulas; G Abatzides; M Karamouzis
Journal:  Br J Sports Med       Date:  1995-12       Impact factor: 13.800

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.